Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
691.82 USD   -1.93%
09:40aRegeneron - dupixent approved by fda as the first and only treatment indicated for prurigo nodularis
AQ
04:13aRegeneron Pharmaceuticals' Dupixent Receives FDA Approval for Chronic Skin Disease
MT
09/28Sanofi-Regeneron's Dupixent Wins First-in-Class US FDA Nod for Chronic Skin Disorder
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

US STOCKS-Strong earnings lift Wall Street ahead of services activity data

08/03/2022 | 09:56am EDT

(Corrects syntax in headline)

* Non-manufacturing activity data due at 10 a.m. ET

* PayPal rises after bumping annual profit outlook

* Airbnb dips after bookings disappoint

* Indexes up: Dow 0.77%, S&P 0.83%, Nasdaq 1.24%

Aug 3 (Reuters) - U.S. stock indexes rose on Wednesday on strong results from PayPal and CVS Health, with investors awaiting services activity data for clues on the health of the economy struggling with soaring inflation and tightening financial conditions.

Shares of PayPal Holdings jumped 11.6% after the fintech company raised its annual profit guidance and said activist investor Elliott Management has an over $2 billion stake.

CVS Health Corp gained 4.7% as the largest U.S. pharmacy chain raised its annual profit forecast after posting strong quarterly results.

A largely upbeat second-quarter earnings season has helped markets bounce back in a year roiled by the Ukraine war, fears of a looming recession and an aggressive rise in borrowing costs.

The benchmark S&P 500 index and tech-heavy Nasdaq are up 13.3% and 18.2%, respectively, from the lows hit in mid-June.

The Institute of Supply Management's data, due at 10 a.m. ET, is expected to show non-manufacturing activity slipped to 53.5 last month from 55.3 in June, the fourth straight monthly decline. The services sector accounts for more than two-thirds of U.S. economic activity.

"What we want is Goldilocks number, big numbers right now are bad, whether they're big and good, or big and bad. What we actually want is pretty small increases or small decreases," said Jason Blackwell, chief investment strategist at The Colony Group.

"That tells us that the Fed is working, (but) not too hard (to) take us into a deeper recession."

Meanwhile, St. Louis Federal Reserve President James Bullard said on Wednesday the U.S. central bank will be steadfast in raising interest rates to bring inflation running at four-decade highs back to its 2% target.

Wall Street started August on a sour note as factory activity in the United States, China and Eurozone weakened in July.

At 9:40 a.m. ET, the Dow Jones Industrial Average was up 250.32 points, or 0.77%, at 32,646.49, the S&P 500 was up 34.03 points, or 0.83%, at 4,125.22, and the Nasdaq Composite was up 152.62 points, or 1.24%, at 12,501.38.

Moderna Inc climbed 8.7% after the vaccine maker announced a $3 billion share buyback plan.

Regeneron Pharmaceuticals added 5.3% after it beat quarterly revenue estimates, while coffee chain Starbucks Corp rose 1% on upbeat quarterly profit.

Advanced Micro Devices Inc fell 2.3% after the chip designer forecast downbeat third-quarter revenue.

Advancing issues outnumbered decliners by a 2.71-to-1 ratio on the NYSE and by a 2.62-to-1 ratio on the Nasdaq.

The S&P index recorded one new 52-week highs and 30 new lows, while the Nasdaq recorded 27 new highs and 10 new lows. (Reporting by Aniruddha Ghosh and Devik Jain in Bengaluru; Editing by Sriraj Kalluvila)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ADVANCED MICRO DEVICES, INC. -6.17% 64.14 Delayed Quote.-52.49%
MODERNA, INC. -3.34% 118.07 Delayed Quote.-51.91%
PAYPAL HOLDINGS, INC. -2.66% 88.7 Delayed Quote.-51.68%
REGENERON PHARMACEUTICALS, INC. -1.93% 691.82 Delayed Quote.11.70%
STARBUCKS CORPORATION -0.62% 86.57 Delayed Quote.-27.95%
All news about REGENERON PHARMACEUTICALS, INC.
09:40aRegeneron - dupixent approved by fda as the first and only treatment indicated for prur..
AQ
04:13aRegeneron Pharmaceuticals' Dupixent Receives FDA Approval for Chronic Skin Disease
MT
09/28Sanofi-Regeneron's Dupixent Wins First-in-Class US FDA Nod for Chronic Skin Disorder
MT
09/28Regeneron Pharmaceuticals, Inc. and Sanofi Announce Approval of Dupixent® by FDA as the..
CI
09/28Sanofi, Regeneron Say Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin Diseas..
DJ
09/20Decibel Therapeutics Files Investigational New Drug Application With US FDA for Product..
MT
09/16Regeneron pharmaceuticals, inc. - positive dupixent phase 3 data in children aged 6 mon..
AQ
09/16Regeneron - POSITIVE DUPIXENT (DUPILUMAB) PHASE 3 DATA IN CHILDREN AGED 6 MONTHS TO 5 Y..
AQ
09/16Intellia Therapeutics, Regeneron Say Genome Editing Therapy Reduced Protein Concentrati..
MT
09/16Sector Update: Health Care Stocks Mixed Premarket Friday
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 824 M - -
Net income 2022 3 884 M - -
Net cash 2022 5 449 M - -
P/E ratio 2022 19,8x
Yield 2022 -
Capitalization 73 961 M 73 961 M -
EV / Sales 2022 5,79x
EV / Sales 2023 5,08x
Nbr of Employees 10 715
Free-Float 80,6%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 691,82 $
Average target price 749,00 $
Spread / Average Target 8,27%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.11.70%75 415
GILEAD SCIENCES, INC.-11.95%80 128
VERTEX PHARMACEUTICALS33.16%74 991
BIONTECH SE-48.10%32 514
WUXI APPTEC CO., LTD.-38.82%28 423
GENMAB A/S-5.29%21 061